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Abstract 
In this paper we describe a complete deletional analysis of hypersensitive site three (HS3) of the human /3-globin Locus 
Control Region (LCR). The previously defined core fragment consists of 6 footprinted regions, with multiple binding sites for the 
erythroid-specific fa tor GATA-1 and G-rich motifs that can interact with ubiquitous factors uch as Spl and TEF-2. We show in 
this paper that the 5' half of this fragment is the most important for activity in murine erythroleukemia (MEL) cells. A fragment 
containing footprints 1-4 can stimulate transcription of a linked human /3-globin gene to levels of about 40% of that obtained 
with footprints 1-6. Constructs containing either footprints 1-3 or 3-6 cannot be distinguished from the/3-globin gene alone. 
We further show that binding sites for the erythroid-specific fa tor NF-E2 can co-operatively interact with parts of the HS3 core 
fragment, and that HS3 requires elements upstream from -103 in the human /3-globin promoter for full activity. The 
importance of these results is discussed in the context of the regulation of the genes in the human /3-globin cluster. 
Keywords: Transcription activation; beta-Globin; Deletion analysis; (Erythroleukemia cell); (Mouse) 
1. Introduction 
The human /3-1ike globin genes are arranged in the 
same order as their developmental expression pattern, 
with the embryonic e-globin at the 5' end, the two fetal 
3' genes in the middle and the adult ]3-globin gene at 
the 3' end [1]. All the genes are controlled by the 
Locus Control Region (LCR) which is located up- 
stream of the • gene, and covers approximately 13 kb 
of DNA. The presence of the LCR is an absolute 
requirement for the high level expression of the genes 
in the cluster [2,3]. The linkage of a human ]3-globin 
transgene to the LCR results in high level, erythroid 
specific expression in mice [4], in sharp contrast to 
constructs lacking LCR sequences which show a low, 
variable expression level [5-8]. The most characteristic 
feature of the LCR is its ability to override position 
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effects when it is stably integrated into chromatin. This 
results in expression levels that are dependent on the 
copy number of the transgene and independent of the 
site of integration in the host genome [4]. This indi- 
cates that it can open up silent chromatin in the 
erythroid environment, with the possible exception of 
heterochromatic regions (D.R. Greaves and F.G., un- 
published ata). 
The LCR is characterized by the presence of four 
erythroid-specific, developmentally stable DNaseI hy- 
persensitive sites [9]. We and others have previously 
shown that the activity of the LCR resides in these 
hypersensitive site (HS) regions and identified the core 
elements as 200-300 bp fragments [10-14]. There is 
strong evidence suggesting that each HS retains the 
essential properties of the LCR, although each site 
varies with regard to the level of transcriptional stimu- 
lation per gene and its developmental specificity [15,16]. 
In this paper, we have focussed our attention on the 
core fragment of HS3, which is transcriptionally the 
most active individual site of the LCR [15,17]. It is a 
225 bp fragment which we have functionally defined in 
both transgenic mice and murine erythroleukemia 
(MEL) cells. It confers position independent expres- 
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sion to a linked fl-globin gene at an expression level of 
40-50% of that achieved with the full LCR [12]. In 
contrast, this site is not active in a typical enhancer 
assay by transient transfections [18,19]. 
With in vitro DNaseI footprinting and gel-retarda- 
tion analysis we found that this fragment has a modu- 
lar structure [12] (Fig. 1B), composed of three foot- 
prints for the erythroid-specific transcription factor 
GATA-1 [20,21] interspersed by G-rich sequences 
which bind ubiquitous factors such as Spl [22] and 
TEF-2 [23]. Using PCR we have made sequential dele- 
tions of these footprints from the 5' and the 3' end, and 
analyzed these for activity in MEL cells. We then 
added binding sites for the erythroid-specific factor 
NF-E2 [24,25] to a subset of these deletions, in order 
to assess whether interactions occur between NF-E2 
sites and the HS3 core fragments. The role of NF-E2 
sites has been studied intensely in the context of HS2, 
another DNaseI hypersensitive site of the human /3- 
globin LCR [10,14,26,27]. This site is transcriptionally 
less active than HS3 and has an entirely different 
architecture [14]. Most notable is a double binding site 
for NF-E2, which is required for high levels of tran- 
scription but which is dispensable for position inde- 
pendent expression [10,27]. There is a consensus e- 
quence for NF-E2 just upstream from the core frag- 
ment of HS3. We were therefore interested to see 
whether binding sites for this protein can functionally 
substitute for deletions in HS3, or synergize with the 
entire core fragment. 
Finally, we addressed the interplay of HS3 and 
upstream sequence lements of the human /3-globin 
gene promoter by testing it in the context of the 
non-erythroid H-2K reporter gene [28-30]. 
2. Materials and methods 
2.1. Plasmid constructions 
All the oligonucleotides used for cloning purposes 
were phosphorylated with polynucleotide kinase. Plas- 
mid GSE 1758 was made by cutting the plasmid GSE 
1273 [31], containing the human /3-globin gene as a 5 
kb BglII fragment, with NotI and HpaI, blunting and 
ligating to a polylinker containing EcoRV, Not I, ClaI, 
HindIII, XhoI, SpeI, Asp718 and SalI sites, recreating 
the HpaI site at -815. (Fig. 1). HS 3 deletions were 
made by the polymerase chain reaction (PCR), using 
the following primers: to generate 3' deletions, oligo 
fpl, sense strand was used in all the reactions, in 
combination with either oligo fp2, 3, 4 or 5 (antisense), 
to create constructs containing footprints 1-2, 1-3, 
1-4 and 1-5, respectively. 5' deletions were made by 
combining oligo fp6, antisense, with either oligo 2, 3, 4, 
or 5 (sense) to obtain constructs containing footprints 
2-6, 3-6, 4-6 and 5-6, respectively. PCR was per- 
formed as recommended by the supplier of Taq poly- 
merase (Anglian Biotechnology). PCR products were 
gel purified, blunted and ligated to HindIII linkers (3' 
deletions) or Asp718 linkers (5' deletions). After diges- 
tion with the appropriate restriction enzymes they were 
cloned in their natural orientation relative to the hu- 
man/3-globin gene in GSE 1758. Constructs containing 
dimers and trimers of footprints 5-6 were generated by 
digesting the construct containing the monomer with 
XhoI and SalI. The purified fragment was ligated to 
itself, digested with XhoI and SalI, and dimers and 
trimers were isolated on a 4% PAA gel. These frag- 
ments were cloned in GSE 1758 digested with Xhol 
A Hpal ~ Bglll TK Neo 
GSE 1 7 5 8 ~  ~ ,' I 
EcoRV 
EcoRV~ Clal Xhol Asp718 
~'~'~i  I , I i I i I  
Nod Hdlll Spel Sail 
B 
2xGATA1 2xGGTGG 2xGATA1 3xGGTGG GATA1 GGTGG 
1-6 1 [ 2 [ 3 l 4 151  6 [ 
C 3' deletions 
1-5 I I I I 
1-4 I I I I 
1-3 I I I I 
1-2 
D 5, deletions 
I I 2-6 [ I I I I [ 
I 3-6 [ I [ I I 
4-6 I I [ [ 
5-6 
Fig. 1. The/3-globin test plasmid and HS3 deletions. (A) GSE 1758 is a plasmid containing the human/3-globin gene as a Hpal-BglIl fragment, a
TK promoter driving a neomycin resistance gene for selection of transfected cells and a polylinker at -815  in the fl-globin gene with the 
indicated restriction sites. (B) Schematic representation of the 225 bp core fragment of HS3. Footprints are labelled 1 to 6. The occurrence of 
GATA-1 motifs and the sequence 'GGTGG'  is indicated above each footprint. (C, D) Sequential deletion of footprints from the 3' (C) or 5' (D) 
end of the core fragment. 
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and SalI. All the constructs were checked by sequenc- 
ing using a Sequenase kit (USB). 
Plasmids containing the non-erythroid mouse H-2K 
gene have been described [28-30]. The HS3 core frag- 
ment containing footprints 1-6 was inserted at position 
-815 in the promoter of the human/3-globin gene. In 
the minimal promoter construct, nucleotides -103 to 
-265 were deleted from the promoter region [30]. 
Sequences of oligonucleotides u ed: 
For PCR: 
oligo fpl, sense: aaGCTGGTGTGCCAGATGTGTC- 
TATCAGAGGTTCCAGGGAGG; 
oligo fp 2, sense: aaATCAGAGGTFCCAGGGAGG- 
GTGGGGTGGGGTCAGGGCTGGCCAC; 
oligo fp 2, antisense: ttTGGCCAGCCCTGACCCCA- 
CCCCACCCTCCCTGGAACCTCTGAT; 
oligo fp 3, sense: aaTGGCCACCAGCTATCAGGGC- 
CCAGATGGGTFATAGGCTGG; 
oligo fp 3, antisense: ttCCAGCCTATAACCCATCT- 
GGGCCCTGATAGCTGGTGGCCA; 
oligo fp 4, sense: aaGCTCAGATAGGTGGTFAGGT- 
CAGGTTGGTGGTGCTGGGTGGAGTCCATGAC- 
TCCCAGGAGCCAG; 
oligo fp 4, antisense: ttCTGGCTCCTGGGAGTCAT- 
GGACTCCACCCAGCACCACCAACCTGACCTAA- 
CCA CCTATCTGAGC; 
oligo fp 5, sense: aaCCATGACTCCCAGGAGC- 
CAGGAGAGATAGACCATGAGTAGAG; 
oligo fp 5, antisense: ttCTCTACTCATGGTCTAT- 
CTCTCCTGGCTCCTGGGAGTCATGG; 
oligo fp 6, antisense: ttCTATGCTGTGCCTCCCCCA- 
CCTTTCCCATGTCTCCCCTCTA; 
HS3-NF-E2, sense: cgGAATVFTGACTCAGCAAA- 
CACAAGACCCTCat; 
HS3-NF-E2, antisense: cgatGAGGGTCTI'GTGTTI'- 
GCTGAGTCAAAATTC; 
HS2-NF-E2, sense: cgatAAGCACAGCAATGCTGA- 
GTCATGATGAGTCATGCTGAGGCITa; 
HS2-NF-E2, antisense: agcttAAGCCTCAGCATGAC- 
TCATCATGACTCAGCATTGCTGTGCTFat. 
2.2. Transfection f MEL cells 
About 5 • 106 cells were transfected by electropora- 
tion with 5-25 /zg of plasmid DNA which was lin- 
earized with PvuI. The transfections were split imme- 
A B 
Probe  FP  1 FP  3 FP  5 -200  Probe:  NF-E2 site HS  2 HS 3 
~ ~ ~ Compet i to r  ~ ~ ~ ~ Compet i to r  ~ ~  ~ ~     , , . , . el, ~ -v - r  ,~ 
X -...11~ 
GATA-1 
Free [ 
NF-E2 
Free 
1 2 3 4 5 6 7 8 91011 1 2 3 4 5 6 
Fig. 2. Band shift assay of GATA-1 and NF-E2 binding sites. Probes and competitors are, as indicated above the lanes, bandshifts were 
performed using MEL nuclear extract. The positions of free probes and retarded complexes specific for GATA-1 and NF-E2 are shown; 'X' 
denotes a ubiquitous protein binding to footprint 1 only. Note that in panel B, the bandshift with the HS3 probe was exposed 10 times longer 
than the bandshift with the HS2 probe. ' -200'  refers to the oligonueleotide covering the GATA-1 site around position -200 in the/3-globin 
promoter [30]. 
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diately after electroporation t  generate three inde- 
pendent populations for each construct. After selection 
in G418, cells were induced by the addition of DMSO 
(2% final concentration) to the media and further 
incubated for four days. DNA was isolated from unin- 
duced cells, while RNA was isolated from induced cells 
[29]. 
2.3. DNA analysis 
Genomic MEL DNA was cut with BgllI, Southern 
blotted and probed for the human ¢J-globin transgene, 
with the mouse Thy-1 gene as a loading control [4]. 
Only populations which harboured the intact ransgene 
were further analyzed. 
A 
1-2 1-3 1-4 2x 1-4 1-5 1-6 2-6 3-6 4-6 5-6 no LCR 
M-~m 
i ~, ~!~ ~ ~ 
1 2 3 4 5 6 7  
B 
8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 
no LCR 1-6 5-6 2x5-6 3x5-6 C88 
I-Iu-13 . . , .  
M-13m 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
Fig. 3. Funtional analysis of HS3 deletions in MEL cells. 20 ~g of total RNA from induced MEL populations, transfected with the constructs as 
indicated on top of the figure, was used for quantitative S1 analysis. The samples were hybridized to probes specific for the 5' ends of mouse 
/3-major (M-/3m; 96 nt protected) and human/3-globin (Hu-/3; 153 nt protected fragment) mRNA.  They were then digested with S1 nuclease, and 
the protected fragments were separated on 6% sequencing els. The protected bands were quantitated with the phosphorimager. Relative 
specific activities of the probes was 1 : 1. 
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2.4. RNA analysis 
Total RNA from MEL cells was isolated as de- 
scribed [12]. 10-20/zg per sample was used for quanti- 
tative S1 nuclease analysis with mixed DNA probes 
specific for the 5' ends of human /3-globin [28] and 
mouse /3-major mRNA [6], or/3-H-2K hybrid mRNA 
[29]. Probe excess was demonstrated by using three 
times the amount of RNA of one particular sample. 
Expression data from S1 sequencing gels were quanti- 
tated using a Phosphor Imager (Molecular Dynamics). 
2.5. Gel mobility shift assays 
Gel mobility shift assays were done essentially as 
described previously [21,30], using 5-10 /zg nuclear 
extract prepared from MEL cells per reaction. The 
oligonucleotides shown above were used as probes and 
competitors. Competitors were added in 100-fold mo- 
lar excess prior to the addition of the extract. 
3. Results 
3.1. Deletional analysis of HS3 
We have previously established that the majority of 
the activity of HS3 is retained on a 225 bp fragment, 
which contains 6 footprints, labelled 1-6 in Fig. 1. 
Footprints 1, 3 and 5 have consensus motifs for the 
erythroid-specific factor GATA-1, while footprints 2, 4 
and 6 have the pentanucleotide s quence GGTGG in 
common. Fig. 2A shows that footprints 1, 3 and 5 are 
capable of binding GATA-1 in a gel retardation assay 
using nuclear extract from MEL cells. In addition, 
footprint 1 also binds a protein designated 'X', which is 
not erythroid specific since it is also present in HeLa 
cells (not shown). As we have shown previously, foot- 
prints 2, 4 and 6 bind Spl, TEF-2 and a number of 
other unknown proteins; none of these appear to be 
erythroid specific [12]. 
We made sequential deletions of these footprints by 
PCR to obtain fragments containing footprints 1-5, 
1-4, 1-3, 1-2 (3' deletions) and 2-6, 3-6, 4-6, 5-6 (5' 
deletions). These were cloned 815 bp upstream from 
the cap site of the human fl-globin gene in the plasmid 
GSE 1758, which contains a neomycin resistance 
marker to allow selection of transformed cells with 
G418 (Fig. 1). After the fidelity of the resulting clones 
was confirmed by sequencing, plasmids were linearized 
with PvuI and stable transformants obtained by elec- 
troporating MEL cells and selection in G418 contain- 
ing media. The cells were induced to differentiate by 
the addition of DMSO and harvested after 4 days. 
DNA and RNA were isolated, transgene integrity was 
monitored by Southern blotting and expression levels 
were assayed by quantitative S1 nuclease protection 
analysis. The results are shown in Fig. 3A and summa- 
rized in Fig. 6. 
It is clear that deletion of footprints from the 5' end 
has a more severe effect than deletion of footprints 
from the 3' end. The 5' deletions how that removal of 
footprint 1 (construct 2-6 in Figs. 3A and 6A) results 
in the loss of 70% of the activity of the entire core 
fragment. This construct still expresses at a higher level 
than the gene alone. However, the additional deletion 
of footprint 2, leaving footprints 3-6, is indistinguish- 
able from the control (Fig. 6A). The result with the 3' 
deletions is that a construct without footprints 5 and 6 
(construct 1-4 in Figs. 3A and 6A) expresses at 40% of 
the level obtained with footprints 1-6, significantly 
higher than the human/3-globin gene without an LCR. 
This is confirmed by the expression level obtained with 
the construct containing a dimer of this fragment (con- 
struct 2 x 1-4 in Figs. 3A and 6A), which approaches 
the level obtained with all 6 footprints. Together these 
data imply that the 5' half of HS3 is the most impor- 
tant for activity and that footprints 1, 2, 4, 5 and 6 are 
functional since their deletion results in decreased 
expression levels. We cannot assess the role of foot- 
print 3 from these experiments, but an internal dele- 
tion of this sequence results in an inactive construct 
(not shown), suggesting that it does have functional 
significance. 
From these data it appeared that multimers of 
GATA-1 sites and GGTGG motifs can functionally 
reconstitute he activity of HS3, and we therefore ad- 
dressed this question directly by testing a monomer, 
dimer and trimer of footprint 5 and 6, the simplest 
combination of a GATA-1 site and a GGTGG motif 
found in HS3 (Fig. 1). The results (Figs. 3B and 6B) 
show that this does not restore activity. We have also 
attempted to restore activity by linking together oligo- 
nucleotides of footprints 1, 2, 3 and 4. However, this 
too failed (data not shown). This inactive construct 
harbours all the sequence information present in the 
active construct containing footprints 1-4 (Figs. 3A 
and 6A), but the spacing between the footprints has 
changed. 
We conclude that simple combinations are inactive 
and do not retain the properties of HS3. 
3.2. Interactions of HS3 with NF-E2 binding sites 
We next investigated the potential interactions be- 
tween HS3 and NF-E2, a factor that has been shown to 
be essential for the function of HS2 of the human 
fl-globin LCR. There is a single consensus for NF-E2 
just upstream from the HS3 fragment containing foot- 
prints 1-6, and we wished to establish first whether 
NF-E2 can bind to this sequence. We analyzed this by 
gel retardation, using the well characterized imer 
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1-3 + 1-3 + 1-6 + 1-6 + 3-6 + 3-6 + 
1-3 3-NFE2 2-NFE2 1-6 3-NFE2 2-NFE2 3-6 3-NFE2 2-NFE2 3-NF-E2 2-NF-E2 no LCR 
m m 
M-[3m 
1 2 3 4 5 6 7 8 9 10 II 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 2930 31 32 33 34 35 36 
Fig. 4. Functional analysis of the addition of NF-E2 bindingsites to HS3 constructs. 3-NF-E2 is the NF-E2 site located 30 bp upstream of the core 
fragment of HS3; 2-NF-E2 is the NF-E2 dimer site of HS2. These were added to the HS3 constructs indicated. Other details are as in Fig. 3. 
NF-E2 binding site of HS2 as a control [14]. As shown 
in Fig. 2B, the HS3 sequence is a genuine NF-E2 
binding site, but it binds much less efficiently than the 
HS2 sequence. The reason for this is not known, but it 
might reflect he difference between a single (HS3) and 
a dimer (HS2) binding site. 
Having shown that the site binds NF-E2 in vitro, we 
made a series of constructs in which we added the HS2 
or HS3 NF-E2 binding sites to the plasmids containing 
footprints l -3 ,  1-6 and 3-6, i.e., the entire core frag- 
ment and the largest 3' and 5' deletion constructs that 
did not give expression levels above background (Figs. 
3A and 6). These constructs were then assayed in MEL 
cells as described above. The result is shown in Figs. 4 
and 6C. 
A moderate increase in the expression level is ob- 
served when just the NF-E2 binding sites are cloned 
upstream of the /3-globin gene, which is in agreement 
with previously published data [14,27]. Addition of the 
HS3 NF-E2 binding site to footprints 1-6 or 1-3 has 
no obvious effect on the expression level obtained with 
these constructs, while addition of the HS2 dimer site 
to these constructs results in a small increase of tran- 
scription. 
Interestingly, when the NF-E2 binding sites are 
cloned upstream of footprints 3-6, we find a significant 
increase in the expression level. As expected, the HS2 
NF-E2 dimer site gives the most pronounced effect, 
stimulating transcription approximately 10-fold. The 
level obtained with this construct is identical to that 
observed with footprints 1-6 (Fig. 6C), indicating that 
the NF-E2 dimer site can functionally replace foot- 
prints 1-2 in the MEL assay. 
However, when the NF-E2 dimer site is tested in the 
context of footprints 1-6, we do not find such a syner- 
gistic increase. We therefore conclude that NF-E2 does 
1-6+full prom. full prom. 1-6+min. prom. min. prom. 
M-[3m 
H-2K i i ! !  ¸ 
1 2 3 4 5 6 7 8 9 10 11 12 
Fig. 5. Promoter equirements of HS3. The promoter egion up to -815 of the human /3-globin gene was fused to the mouse H-2K reporter 
gene, and the core fragment of HS3 was cloned at - 815. To obtain the minimal promoter construct, nucleotides - 103 to - 265 were deleted 
from the promoter. These constructs were then tested in stably transfected MEL cells. For SI analysis, probes pecific for the 5' ends of l-H-2K 
hybrid mRNA (85 nt protected fragment) and mouse /3-major (M-/3m) mRNA were used. Relative specific activities of the probes: 
H-2K/M-Bm = 10: 1. 
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not play a major part in the function of HS3 in MEL 
cells. 
3.3. The human fl-globin gene promoter and transcrip- 
tional activation by HS3 
The promoter and enhancer of the human/3-globin 
gene contain binding sites for erythroid and ubiquitous 
transcription factors [21,30]. It is possible that the 
transcriptional activation observed with the HS3/f l -  
globin constructs in this study is due, at least in part, to 
these local genetic elements. We therefore investigated 
the requirements of HS3 for promoter elements by 
linking footprints 1-6 to the fl-globin promoter (up to 
-815) and cloning this in front of a non-erythroid 
H-2K reporter gene [28,30]. 
We have shown previously that, in the absence of 
the LCR, elements between -103 and -265 are re- 
quired for inducibility of the human/3-globin promoter 
in MEL cells [28,30]. However, in the presence of the 
microlocus LCR [31], promoter elements upstream 
from - 103 appear to be redundant, while the presence 
of the minimal promoter is sufficient to obtain the full 
level of expression [29]. The minimal promoter consists 
of a CACC box at -95,  a CCAAT box at -80,  and a 
TATAA box at -30  [30]. We deleted nucleotides 
-103  to -265  to investigate whether footprints 1-6 
can function through the minimal promoter. 
A 
I-2 1-3 I-4 
(8)  (9) (9) 
i 
2xi-4 I-5 
(6) (6) 
I 
/ / /  
/ 
i 
I-6 
(131 
II 
i i I v i I i 
2-6 3-6 4-6 5-6 no LCR Corarroo 5-6 ~5-6 3x5-6 no LCR Co~tmcl 
(5) (9) (8) (9) (15) m of pop, (9) (3) (3) (15) m ot pop. 
/ /  
/ /  
/ /  
/ /  
/ /  
/ /  
/ /  
/ /  
/ /  
/ /  
/ /  
/ /  
/ /  
/ /  
o / /  
I-6 
( l])  
C D 
150 
I00 
50 
1-3 I-3 (6) + 1-3 (6)  + 
(9) 3-NI:-E2 2- NI:-F.2 
, 
I 
1.6 1,6(5)+ 1.6(5)~- 
(13) 3-NF. E2 2-NF-E2 
T / /  
I I 
I~O 
1{30 
o 
i i i 
3.6 3.6(6)~. 3-6(6)+ 3-N|:-E2 .NF.E2 aoLCR Canst t~o 1.6+f~ll t~llpmm, l-6+mln, mia. lnt~. Coratt~t¢l  
(9) 3-N|:- E2 2- NF-E2 (5) (5) (15) J of pop. prom, (3) (3) prom. (3) (3) m of  pop. 
T \ \  
\ \  
\ \  
\ \  
\ \  
\ \  
\ \  
\ \  
\ \  
\ \  
\ \  
\ \  
\ \  
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\ \  
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x x 
i i 
Fig. 6. Quantitative analysis of HS3 constructs in MEL cells. Expression data were quantitated from $1 gels using the phosphorimager. The 
expression level obtained with the construct containing footprints 1-6 was arbitrarily set at 100%. The number of populations analyzed for each 
construct is indicated between parentheses. Error bars represent standard deviations. 
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The results obtained with the constructs containing 
footprints 1-6 show that HS3 is capable of activating 
the full /3-globin promoter when attached to the H-2K 
gene (Figs. 5 and 6D). This result is in agreement with 
that reported for the microlocus LCR [29]. In this 
earlier study, no difference was found between con- 
structs containing the full or the minimal promoter of 
the/3-globin gene. A 2-fold reduction in the expression 
level of the minimal promoter construct was observed 
after deletion of HS3 from the microlocus, leaving 
HS1, 2 and 4. Interestingly, we observe a more severe 
reduction when we test the HS3 core fragment with the 
the minimal p romoter /H-2K  construct. The expression 
level is five times lower than that obtained with the full 
promoter, demonstrating hat in MEL cells HS3 inter- 
acts with protein binding sites in the upstream pro- 
moter from -103  to -265.  Most notably, the up- 
stream promoter of the/3-globin gene contains a strong 
GATA-1 binding site at -200  [30]. It is important o 
recognise however that HS3 can activate both the full 
and the minimal promoter when attached to the non- 
erythroid H-2K gene. 
4. Discussion 
In this paper we have investigated some of the 
parameters governing the activity of HS3 of the human 
/3-globin LCR. We have analyzed the core fragment by 
progressive removal of footprinted areas from either 
the 5' or the 3' end. The results show that the 5' half of 
the core fragment is the most important for expression. 
The removal of footprint 1, a GATA-1 site, results in 
the loss of 70% of the activity of HS3. Subsequent 
removal of footprint 2 abolishes expression to the level 
observed with the gene alone. Deletions from the 3' 
end of footprints 6 or 5 and 6 results in a reduction of 
expression to 47 and 40%, respectively, of that ob- 
tained with the full site. An important conclusion from 
these data is that both GATA-1 sites (footprints 1, 3 
and 5) and the G-rich motifs (footprints 2, 4 and 6) 
have a functional role, since we observe an effect on 
expression if we remove either type of footprint. More- 
over, in a parallel study in transgenic mice we have 
shown by point mutagenesis that the GATA-1 sites in 
footprints 1 and 3 and the G-rich motif in footprint 2 
are absolutely required for the LCR activity of HS3 
[32]. These data are consistent with the results we 
report here. Interestingly, in vivo footprinting data 
have been recently published for HS3 [33]. Orkin and 
co-workers [32] have demonstrated that protein-DNA 
interactions occur in vivo at footprints 1 to 5, in agree- 
ment with our results. The only discrepancy between 
this report and the in vivo footprinting data occurs at 
footprint 6. Footprint 6 is not footprinted in vivo, but 
its deletion leads to a reduced expression level in our 
assay (Figs. 3A and 6A). This discrepancy may be 
explained by the fact that footprint 6 is a relatively 
weak protein binding site which as a result is occupied 
too infrequently to be detected with the in vivo foot- 
printing technique. 
From our previous work the interesting question 
arose whether HS3 simply depends on a certain num- 
ber of footprints containing the GATA-and the G-rich 
motif, or whether in addition these need to be in a 
particular arrangement. The minimum number of foot- 
prints required to obtain activity in the MEL transfec- 
tion system used in this study is four, as demonstrated 
by the construct containing footprints 1-4. This con- 
struct consists of GATA-1 binding sites in footprints 1 
and 3 and G-rich sequences in footprints 2 and 4. 
Duplication of this fragment results in an additive 
increase in the level of expression. However, when we 
tried to mimic this situation by testing 1, 2 and 3 copies 
of footprints 5 and 6 (a GATA-1 site and a G-rich 
motif), we did not restore expression to the levels 
observed with either footprints I -4  or 1-6. The expres- 
sion level remained indistinguishable from that ob- 
tained with the gene alone. In a separate attempt we 
combined a synthetic GATA-1 site with a consensus 
for the G-rich motif and inserted 1 to 6 copies of this 
module into the/3-globin test plasmid. Again, we failed 
to obtain expression levels above background (data not 
shown). In addition, we cloned oligonucleotides cover- 
ing footprints 1, 2, 3 and 4 into the test plasmid. This 
construct now contains all the sequence information 
present in the construct containing footprints 1-4, but 
the spacing between the footprints has changed. This 
construct was also inactive. Although these are three 
lines of negative vidence, they support our notion that 
the protein binding sites in HS3 have to be in a 
particular spatial arrangement in order to create a 
functional entity. Activity is therefore achieved through 
synergistic interactions between the individual ele- 
ments only if the appropriate spacing requirements 
have been fulfilled. 
The construct with footprints 1-4 may not be the 
minimal construct with LCR activity due to limitations 
of the transfection assay. Since transfected cells have 
to be selected for resistance to G418, i.e., expression of 
the neomycin gene, the populations obtained are bi- 
ased for productive integrations f the constructs. This 
results in an artificially high expression level of non- 
LCR containing constructs. Our work in transgenic 
mice [32] has shown that constructs containing foot- 
prints 1-3 or 3-6, which are indistinguishable from the 
background in the MEL cell system, are the smallest 
constructs with LCR-like properties. 
The only erythroid-specific factor found to interact 
with the core fragment of HS3 so far is GATA-1. We 
therefore determined whether another erythroid- 
specific factor, NF-E2 [24,25], could play a part in 
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transcriptional ctivation by HS3. In HS2 of the human 
/3-globin LCR, a dimer binding site for NF-E2 has 
been shown to be responsible for the high levels of 
transcriptional activation achieved with this site 
[10,26,27]. HS3 contains a single consensus binding site 
for NF-E2 30 bp upstream of the core fragment con- 
taining footprints 1-6. Both the HS2 and HS3 NF-E2 
binding sites are footprinted in vivo [33-35], but func- 
tional data to establish the role of NF-E2 in the activity 
of HS3 have not, as yet, been reported. It was there- 
fore of interest o see whether the addition of NF-E2 
binding sites to HS3 constructs would have any effect 
in vivo. Addition of the HS3 NF-E2 site did not appear 
to have any effect on the expression of constructs 
containing footprints 1-6 and 1-3. This would argue 
that NF-E2 is not important in the context of HS3, and 
is consistent with the observation that HS2 and HS3 do 
not synergize when tested in cis [17,29]. However, 
addition of the HS2 NF-E2 dimer site to the otherwise 
inactive construct containing footprints 3-6 does result 
in a synergistic enhancement of transcription. We con- 
clude from this that NF-E2 can substitute at least 
partly for the functions retained in footprints 1 and 2, 
and that its activity may be obscured in the presence of 
these footprints in the MEL system. Interestingly, when 
we originally mapped the core fragment of HS3, we 
noticed that although it gave the full level of activity in 
transfected MEL cells, the expression level in trans- 
genic mice was reduced to about 60% of that obtained 
with a larger fragment, which includes the NF-E2 site. 
We suggested that this reduction might be caused by 
the loss of this NF-E2 motif, and the results presented 
here support this view. NF-E2 is not as vital for the 
functioning of HS3 as it is for HS2. Addition of the 
HS2 dimer site to the HS3 fragment containing foot- 
prints 1-6 results in a moderate increase of expression 
(Figs. 4 and 6C). In the case of HS2, deletion of this 
site results in a dramatic decrease in the expression 
level [10,14,27]. This highlights a fundamental differ- 
ence between these two elements of the LCR, which 
have a totally different architecture [12,14]. It suggests 
that the stimulation of transcription by NF-E2 is highly 
dependent on the context of ther surrounding binding 
sites. 
Finally, we started investigating the promoter re- 
quirements of HS3, by asking whether the minimal 
/3-globin promoter [30] is sufficient o obtain the level 
of expression obtained with the full promoter, as has 
been shown to be the case for the microlocus LCR [29]. 
The data show that HS3 requires the intact promoter 
to function fully. This paradox may be explained by 
distance ffects. In humans, the LCR is situated 50 kb 
upstream of the human /3-globin gene, which is much 
more than in our constructs. A large reduction in 
distance between the LCR and the /3-globin promoter 
may circumvent the requirement for the upstream pro- 
moter, since this reduction might facilitate interactions 
between the LCR and the promoter. Our results indi- 
cate that the upstream promoter could be functional in 
vivo. We have recently been able to generate trans- 
genic mice containing the intact 70 kb human/3-globin 
locus [36]. This has opened up the way to investigate 
these questions in the closest possible approximation to
the in vivo situation. 
In addition, it should be noted that the promoter of 
the TK-neo gene might compete with the globin pro- 
moter for HS3. The TK promoter may therefore com- 
pete more successfully for HS3 with the minimal pro- 
moter than it does with the full promoter, resulting in 
an increased expression level of the TK-neo gene, at 
the expense of the transcription of the /3-globin gene. 
This suggests that the upstream promoter is involved in 
the switch from fetal to adult globin expression, a 
process in which the relative position of the genes in 
the gene cluster and their ability to compete for the 
LCR have been proposed to be key factors [37-39]. 
As to the mechanism of transcriptional ctivation by 
HS3, there may be some common elements between 
HS3 and the promoter, notably the GATA-1 site at 
-200  and the CACC box at -95  in the promoter and 
the modular array of GATA-1 sites and GGTGG 
(CCACC) motifs in HS3. Since the most widely 
favoured model [40] for gene activation postulates di- 
rect interaction between the activating sequences and 
the promoter, with the intervening DNA looping out 
(the 'looping model'), interactions between HS3 and 
the /3-globin promoter may occur through these com- 
mon motifs. However, the spatial arrangement of these 
elements appears to be very different between the 
promoter and HS3, making it difficult to envisage how 
these interactions are achieved. We are currently de- 
signing assays to investigate the validity of the looping 
model both in vitro and in vivo. 
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